CenterBook Partners LP acquired a new position in shares of Agilent Technologies, Inc. (NYSE: A) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,386 shares of the medical research company's stock, valued at approximately $1,333,000. Other institutional investors and hedge funds
Get a deeper insight into the potential performance of Agilent (A) for the quarter ended January 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Assetmark Inc. increased its position in Agilent Technologies, Inc. (NYSE: A) by 6.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 221,291 shares of the medical research company's stock after purchasing an additional 12,997 shares during the quarter.
Bloomberg's 2026 Dividend Focus list highlights 16 'safer' stocks with free cash flow yields exceeding dividend yields, signaling strong dividend sustainability. Top projected net gains for 2026 include PT Telekom at 70.36%, with average net gain estimates of 28.13% across the top ten dividend-focused stocks. Five 'IDEAL' stocks—Continental, Aviva, PT Telekom, Danske Bank, and Western Midstream—offer dividends from $1,000 invested that exceed their single share price.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti.
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #CircularEconomy--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC.
Envestnet Asset Management Inc. grew its stake in Agilent Technologies, Inc. (NYSE: A) by 3.8% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 607,914 shares of the medical research company's stock after buying an additional 22,498 shares during the quarter. Envestnet Asset Management Inc. owned
Federated Hermes Inc. lessened its holdings in Agilent Technologies, Inc. (NYSE: A) by 82.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,128 shares of the medical research company's stock after selling 10,153 shares during the quarter. Federated Hermes Inc.'s
Investors seeking protection from geopolitical volatility and stubborn inflation in 2026 may find opportunity in short-term bonds, where active management has historically delivered returns 25% higher than passive strategies, according to Vontobel Asset Management. Research going back to the 1990s shows investors in short-term, high-quality corporate bonds typically earn total returns of 1.
